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Abstract: This review aimed to systematically review what has been published regarding tinnitus 
during the coronavirus disease 2019 (COVID-19) pandemic up to March 2021 by performing both 
narrative and quantitative meta-analyses. Of the 181 records identified, 33 met the inclusion criteria, 
which generally had a fair risk of overall bias. In the included, 28 studies focused on the impact of 
the COVID-19 virus on tinnitus and 5 studies focused on the impact of the pandemic on tinnitus. 
From the studies identifying the impact of COVID-19 on tinnitus, there were 17 cross-sectional 
studies (n = 8913) and 11 case series or case report studies (n = 35). There were 2 cross-sectional 
studies (n = 3232) and 3 pre-post-test design studies (n = 326) focusing on the impact of the pandemic 
on tinnitus. No consistent patterns were found regarding the presentation of the tinnitus or 
additional factors that could have tinnitus developing in the disease impact studies. For the 
pandemic impact studies, the associated stress and anxiety of the pandemic were consistently 
suggested to contribute to tinnitus experiences. The pooled estimated prevalence of tinnitus post 
COVID-19 was 8% (CI: 5 to 13%). Medical professionals should be aware that tinnitus might be 
more problematic following the pandemic or after having COVID-19. 




On 11 March 2020, weeks after discovering a rapidly spreading Severe Acute 
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the World Health Organisation 
(WHO) declared the coronavirus disease 2019 (COVID-19) outbreak a global pandemic 
[1]. A wide range of symptoms has been associated with contracting COVID-19, including 
respiratory failure, fever, headaches, and loss of taste and smell [2]. The severity of these 
symptoms ranges from being asymptomatic to having fatal consequences [3]. In addition, 
auditory-related conditions such as dizziness, tinnitus, and otalgia have been identified 
as common COVID-19 symptoms [4]. The duration of the symptoms also varies from 
being acute (lasting up to 4 weeks), ongoing (lasting 4–12 weeks), or lasting more than 12 
weeks, referred to as “long COVID” [4]. According to the National Institute for Health 
and Care Excellence (NICE) [4], common symptoms of long COVID include dizziness, 
tinnitus, and otalgia. This is plausible since several viral infections have been identified to 
directly damage the inner ears; increase susceptibility to fungal or bacterial infections; or 
induce inflammatory responses such as measles, rubella, and cytomegalovirus [5,6]. 
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The prevalence of audio-vestibular symptoms following the contraction of COVID-
19 has been estimated by numerous systematic reviews. The first, by Almufarrij et al. [7], 
was published from searches in May 2020, followed by one by Saniasiaya [8] and Maharaj 
et al. [9] regarding searches in July 2020. A systematic review undertaken in December 
2020 investigating audio-vestibular symptoms following contracting COVID-19 indicated 
that tinnitus had an estimated prevalence of 14.8% (CI: 6.3 to 26.1) from 12 studies [10]. 
Other audio-vestibular symptoms were less prevalent, such as hearing loss (7.6%; CI: 2.5–
15.1) and vertigo (7.2%; CI: 0.01–26.4). A further review by Jafari et al. [11] indicated a 
lower prevalence range (4.5%; CI: 1.2 to 15.3) from six studies. 
Due to the alarming spread of the virus through human-to-human transmission, 
many countries enforced regional lockdowns to reduce social interactions [12]. Although 
these measures reduced the spread of the virus, the restrictive measures imposed lead to 
a negative impact on wellbeing and increased mental health difficulties in the general 
population [13–16]. Certain populations were identified as being at higher risk of the 
pandemic negatively impacting them. This included those with tinnitus, due to the 
bidirectional relationship between stress and tinnitus, resulting in tinnitus being initiated 
or exacerbated during stressful periods [17]. As tinnitus is known to impact people 
differently, the effect of the pandemic on pre-existing tinnitus was unknown. Initial 
studies reported a range of outcomes such as some individuals finding tinnitus to be stable 
and others finding it worse (e.g., Beukes et al. [18]). 
The systematic reviews to date have helped identify estimates of tinnitus and other 
auditory-vestibular dysfunctions. There is, however, not much known about the 
presentations of tinnitus, which will be further explored by this review. This is in aid of 
identifying possible risk factors, patterns in the tinnitus presentations, the tinnitus onset 
post-infection, and whether it resolves or changes. As no review has focused specifically 
on tinnitus or incorporated the effect of the pandemic on tinnitus, this review aimed to 
include these effects. The specific aims were to (i) investigate the effect of contracting 
COVID-19, (ii) determine the impact of the pandemic on tinnitus experiences, (iii) identify 
the progression and characteristics of the tinnitus, and (iv) comprehensively evaluate 
factors that could contribute to understanding the association between COVID-19 and 
tinnitus. 
2. Materials and Methods 
2.1. Protocol and Registration 
This systematic review was prospectively registered with the International 
Prospective Register of Systematic Reviews (PROSPERO number CRD42021235661, 
registered on 10 February 2021) where the protocol can be found. No changes were made 
after registration to the protocol. The methods selected were guided by the Preferred 
Reporting Items for Systematic reviews and Meta-analyses (PRISMA; see Table S1)[19]. 
As this was a review, registration with an institutional review board was not required.  
2.2. Eligibility Criteria 
Eligibility was determined according to the PCECOS Criteria (Table 1). The 
population of interest was those experiencing tinnitus during the COVID-19 pandemic or 
due to COVID-19. Populations describing other audiological symptoms without any 
tinnitus were excluded. The primary outcome was tinnitus associated with the COVID-19 
virus and the COVID-19 pandemic. Secondary outcomes were reporting any other 
hearing-related symptoms such as hearing loss or vestibular complaints. Any 
interventions or diagnostic tools managing COVID-19 or the effects of the pandemic were 
included. All studies (cohort, cross-sectional, case report, case-control studies, and 
commentaries), irrespective of the study design, were included but systematic reviews 
were excluded. Unpublished data, pre-prints, and secondary publications of the main 
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published paper were excluded. All language publications were included with no date 
restrictions. 
Table 1. Inclusion and exclusion criteria for the review. 
  Inclusion  Exclusion  
Population  
Individuals of any age experiencing 
tinnitus during the COVID-19 
pandemic or due to contracting SARS-
CoV-2 (COVID-19).    
Individuals without tinnitus   
Condition  
Tinnitus, which is the perception of 
sound in the ears or head in the 
absence of any external sound.   
No tinnitus  
Exposure  
Confirmed, probable, or suspected 
exposure to COVID-19 or the 
pandemic.   
Not exposed to COVID-19 or the 
pandemic.  
Comparator  Not applicable   Not applicable  
Outcomes  Self-reported experiences of tinnitus  No tinnitus reports  
 Study designs  
Any study designs, including 
commentaries and case studies  
Systematic reviews, secondary studies 
discussing other studies  
Timings  At least one time point  
No exclusions regarding the length of 
follow up assessments  
Language   All languages  None  
2.3. Information Sources  
The following electronic research databases were used: PubMed (MEDLINE), 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), Academic Search 
Complete, and EBSCOhost including Web of Science. Additional searches included hand-
searching key journals and the reference lists from the included studies, citation tracking, 
and grey literature in Google Scholar. Unpublished data, including preprints, were 
excluded. 
2.4. Search Strategy 
A peer-reviewed search strategy was developed and tested through an iterative 
process. The keywords ‘tinnitus’ AND ‘COVID-19′ OR ‘coronavirus’ were used for 
searching. The search terms were used with Boolean operators and in combination with 
MeSH terms for each search engine to maximize outputs from the literature search. The 
searches were re-run until 31 March 2021, before the final analysis to ensure that no 
relevant articles were missed. Table S2 provides the search strategy results, including the 
number of records returned. Three authors (EB, AU, and TE) independently searched the 
databases and screened the studies to identify which met the inclusion criteria by viewing 
the abstracts between 15 and 20 February 2021. Periodically, until submission, searches 
were redone during the review process to assess for any further studies up to 31 March 
2021. Included studies were cross-referenced with previous related reviews. 
2.5. Data Management and Study Selection  
The records were exported to Rayyan [20] for independent blinded eligibility 
screening by three reviewers (EB, AU, and TE). Duplicate records were identified and 
manually removed. The title and abstract were screened, and the full text was inspected 
when required. For records passing the initial screen, the full texts were subsequently read 
to determine eligibility.  
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2.6. Data Collection Process and Data Items 
For each study, relevant data suggested by the PRISMA were extracted onto a data 
extraction Excel spreadsheet designed by the researchers for purposes of this review. The 
manuscripts were divided for extraction by three authors (AU, TE, and EB) and cross-
checked by each other. Initially, descriptive data were extracted regarding the reference, 
country, population, sample size, study design, mean age, and gender ratios. In addition, 
the following outcomes were extracted: reports of tinnitus, reports of tinnitus changes, 
and reports of other audio-vestibular difficulties (see Tables 2–4). Symptoms of dizziness, 
disequilibrium, and balance problems were classified as vestibular disorders. 
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2.7. Risk of Bias Assessment 
Due to the different types of study designs included in this review, quality 
assessment for the included studies was assessed using the National Institute of Health 
Quality Assessment Tools [53]. Although other tools are available, using the same tool as 
used in similar systematic reviews (e.g., Almufarrij and Munro [10]) allowed for 
consistency. Specifically, the Quality Assessment Tool for Case-Control Studies, for 
Observational Cohort and Cross-Sectional Studies, and for Before-After (Pre-Post) Studies 
with No Control Group were used depending on the study design. The included studies 
were assessed for risk-of-bias following the 9–14 questions on each checklist (see Table 
S3). Each item was judged blinded and independently by two reviewers (AU and TE). 
These ratings were compared and verified by a third reviewer (EB). An overall quality 
rating was made as good (unbiased and fully described), fair (unbiased results despite 
missing data), or poor (substantial details missing or questionable results). 
2.8. Strategy for Data Synthesis 
This review focused on synthesizing factors that may contribute to the presence of 
tinnitus by using a formal narrative synthesis as described by Campbell et al. [54] and 
Popay et al. [55]. The synthesis was conducted independently by three reviewers, and the 
combined agreed results were reported. Meta-analysis was conducted to pool the 
prevalence of tinnitus from the cross-sectional studies. The pooled estimates and 95% CI 
were computed using Comprehensive Meta-Analysis version 3 [56]. The model selected 
(fixed or random-effect) would depend on statistical heterogeneity. If I2 is high (larger 
value), indicating that effect sizes vary across the included studies, a random-effect model 
would be used to pool the data [57]. The results will be presented in a Forest Plot. 
2.9. Subgroup Analysis  
Subgroup analysis of the included studies included those describing the disease 
impact of COVID-19 on tinnitus and those looking at the impact of the pandemic on 
tinnitus. Subgroup analysis was then done depending on study design, i.e., cross-
sectional, pre-/post-test designs, or case studies/case controls. 
  




3.1. Study Selection 
Database searching identified 181 retrieved records. After removing duplicates, 65 
records were screened for inclusion. Of these, 33 studies met the inclusion criteria (see 
Figure 1). Potential studies were most often excluded due to not fulfilling the criteria of 
outcomes and study design or being a pre-print and not yet published. All studies 
included were published in 2020–2021 with data collection between January and October 
2020. Most studies were specific to a single country, including regions of China, Brazil, 
Qatar, Germany, Turkey, the United Kingdom, Malaysia, Egypt, Turkey, Italy, Iran, India, 
and the United States. There were two international studies [18,33] and one regional study 
in Europe [41]. All the studies were in English, except one which was in Russian [32]. A 
translated copy was obtained to include in this review. Where numbers were not clearly 
stated regarding individuals with tinnitus, the study authors were contacted for 
clarification (e.g., Davis et al. [33]). 
 
Figure 1. Prisma Flowchart. 
3.2. Study Characteristics 
Due to the variation in the studies included in this systematic review, they were 
grouped initially by research question. There were 28 studies investigating the impact of 
COVID-19 disease on tinnitus and 5 studies investigating the impact of the COVID-19 
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pandemic on tinnitus. Due to the heterogeneity of the studies investigating tinnitus 
initiation following contracting COVID-19, the studies were further grouped into case 
reports and case series studies or cross-sectional studies. Among the disease impact 
studies, there were 11 case series/reports (Table 2) and 17 cross-sectional studies (Table 3). 
Among the pandemic impact studies, there were two cross-sectional, and three pre-/post-
test study designs (Table 4). Findings from these studies are summarized in the next 
sections. 
3.3. Risk of Bias in the Individual Studies 
The quality assessment analyses of individual included studies are provided in 
Tables 2–4 and Table S3. Overall, the study designs included were of low quality relative 
to the hierarchy of evidence in trials as no randomized controlled trials were included. 
The quality of the included studies was, however, fair in most cases (n = 25, 78%), with 4 
(12.5%) being rated good, and 3 (9.5%) studies being rated poor, generally due to lacking 
details. The included studies thus generally provided unbiased accounts of tinnitus 
descriptions. The results of the individual studies are presented in the next sections. 
3.4. Case Reports/Case Series Disease Impact Studies  
3.4.1. Study Characteristics 
There were 11 case reports documenting the onset or aggravation of tinnitus, 
sometimes reported together with other audio-vestibular symptoms (see Table 2). There 
were 35 cases in total with 9 case studies, 20 cases by Cui et al. [22], and 6 by Karimi-
Galougahi et al. [25]. Most studies were specific to a single country, including Germany 
[23], the State of Qatar [21], United Kingdom [26], Ireland [28], Brazil [27], Turkey [24], 
Malaysia [29], Egypt [30], China [22,31], and Iran [25]. There was great variability in the 
ages of the patients, with the youngest being 23 years and the oldest being 67 years, with 
an overall mean of 42 years. Of the 14 patients with tinnitus, 6 were male (43%) and 8 were 
female (57%).  
3.4.2. Pre-Existing Health Conditions 
Most studies reported no pre-existing head trauma, ototoxic medication, or hearing 
disorders. Pre-existing health conditions were described in three studies, including 
mediated rheumatoid arthritis [27], medicated asthma [26], diabetes, hypertension, and 
Meniere’s disease [22]. Five studies reported no relevant comorbid diseases [,24,25,28-30.], 
and comorbidities were not described in three studies [21,23,31]. Hence, a range of 
medical backgrounds was found for these case studies.  
3.4.3. Tinnitus Characteristics 
In total, 14 patients (40%) reported tinnitus in the case reports included in this review. 
Few of the case reports provided clear descriptions of the tinnitus experienced. Where 
provided, great variability was found, for example, a 4 kHz and 10 dB sensation level 
using a tinnitus evaluation [21]; loud, white noise in both ears [23]; non-pulsatile [29]; 
disabling [27]; and gradually worsening [30]. There was no consistency regarding the 
location of the tinnitus, reported bilaterally [23], right-sided [28,29], and left-sided [21,23]. 
The remaining three case reports [22,24,25] reported aggravation or onset of tinnitus 
during COVID-19 without any descriptive information. Chirakkal et al. [21] was the only 
study that utilized a tinnitus evaluation comprised of frequency and intensity matching.  
3.4.4. Tinnitus Initiation 
The exact timings of the tinnitus initiation post-COVID-19 were furthermore lacking. 
Chirakkal et al. [21], Fidan [24], Lamounier et al. [27], Maharaj and Hari [29], and Sun et 
al. [31] reported the onset of tinnitus with the diagnosis of COVID-19. Degen et al. [23] 
reported tinnitus alongside deafness after the patient’s recovery following thirteen days 
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in the intensive care unit (ICU) for COVID-19, and Koumpa et al. [26] reported tinnitus a 
week after transferring out of the ICU. Lang et al. [28] reported tinnitus onset after 
recovery from COVID-19. The remaining studies were unclear regarding the onset of 
tinnitus. 
3.4.5. Tinnitus Persistence or Recovery 
Only two of the studies mentioned recovery of tinnitus. One study was two months 
post-recovery [29], and the other mentioned alleviation of dizziness and tinnitus following 
treatments with betahistine, a dihydrochloride tablet often used to treat vertigo symptoms 
[22]. Other studies reported tinnitus to persist post-recovery [21,27]. The remaining 
studies did not elaborate on tinnitus duration. Thus, a need for follow-up assessments 
regarding the recovery or persistence of tinnitus can aid in the understanding of the 
impacts of COVID-19 disease and treatment on tinnitus. 
3.4.6. Hearing Loss 
One patient reported conductive hearing loss in the right ear [24], and eight patients 
reported sudden sensorineural hearing loss as a potential COVID-19-related symptom 
(total n = 12, 33%) [21,23,24–28,,30,31]. Bilateral hearing loss was found in two patients 
[23,27], and 10 presented unilateral hearing loss, with 5 in the right ear [21,25,28], 4 in the 
left ear [23,25,26,30], and one patient presented unspecified hearing loss [31].  
Pre-existing hearing loss was described in some studies, with only one patient 
presenting with hearing loss before coronavirus confirmation [27]. Lamounier et al. [27] 
reported audiological testing prior to the pandemic revealing isolated hearing loss at 
frequencies 6 and 8 kHz in the right ear only with thresholds being 45- and 30-dB HL, 
respectively. Audiological outcome measures to confirm hearing loss after the contraction 
of COVID-19 varied and included pure tone audiometry (air- and bone conduction), pure 
tone audiometry (bone-conduction only), acoustic immittance, speech audiometry, 
otoacoustic emissions, acoustically evoked potentials, and bedside testing with tuning 
forks. Variability in outcome measures yielded diverse reporting measures of audiological 
testing. Diagnostic imaging was furthermore utilized in some studies to aid in the 
confirmation of hearing loss. For instance, Degen et al. [23] reported magnetic resonance 
imaging (MRI) findings of the right and left cochlea revealing inflammation of the 
meninges and the right cochlea, consistent with a diagnosis of a dead right ear. Following 
diagnosis, the stability and management of hearing loss were unclear in most studies. 
Management of hearing loss was discussed in a few studies, such as via medication, 
corticosteroid therapy (the most common), and amplification. Where provided, three 
studies reporting the use of corticosteroids revealed improvement [26,27,30] and one 
study revealed no improvement in hearing sensitivity [34]. For example, isolated 
improvements in hearing following combined corticosteroid therapy (oral and 
intratympanic) were reported in Lamounier et al. [27] at 0.25 kHz in the right ear (from 60 
dB, the threshold became 15 dB) and at 4, 6, and 8 kHz in the left ear (the thresholds 
became 15 dB, 5 dB, and 20 dB, respectively). Management of hearing loss using 
amplification, specifically cochlear implantation, was reported in only one study [23] 
following MRI findings indicative of inflammatory processes in the cochlea. Due to 
concerns regarding soft tissue formation or ossification, which could hamper surgical 
insertion of the electrode, urgent implantation was recommended. 
3.4.7. Vestibular Impairment 
Vestibular difficulties associated with coronavirus were reported in only three 
patients (8%), all with positive results when tested for the coronavirus. Information 
regarding vestibular dysfunction was limited. Cui et al. [22] reported tinnitus and 
dizziness for a 52-year-old male with a history of diabetes and Meniere’s disease, which 
was alleviated with betahistine, a commonly prescribed drug for balance disorders used 
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to alleviate vertigo symptoms. Due to the coexistence of Meniere’s disease, which 
manifests such symptoms with coronavirus, it is difficult to determine a connection 
between the virus, dizziness, and tinnitus in this case report. Treatment, stability, or 
recovery were not discussed. Lastly, Maharaj and Hari [29] presented a 44-year-old male 
admitted to the hospital after experiencing acute onset of spontaneous vertigo with 
nausea/vomiting and right-sided non-pulsatile tinnitus. His hearing was in the normal 
range and bedside vestibular testing and caloric testing revealed weakness in the semi-
circular canal. Specifically, a tendency to fall towards the right side and associated 
horizontal torsional spontaneous nystagmus beating toward the unaffected side was 
reported. Management or follow-up was not discussed in the study. 
3.4.8. COVID-19 Testing 
COVID-19 testing (positive or negative) information was included in most studies, 
with reverse transcription-polymerase chain reaction (RT-PCR) test being the most used. 
Three studies used both RT-PCR and radiographic imaging to diagnose coronavirus 
[24,25,31,]. Three studies used only RT-PCR [23,27,30], one study used an unspecified 
throat swab [29], another study used an unspecified nasopharyngeal swab [28], and the 
remaining studies did not report the method for diagnosis [21,22,,26]. All patients tested 
positive, except in one study [25] that enrolled two participants with negative RT-PCR test 
results reporting tinnitus and hearing loss. Of the patients that tested positive, eight 
patients were symptomatic with typical features of COVID-19, such as pneumonia, fever, 
and coughing; three patients were asymptomatic; and one patient’s symptoms were not 
described although she had no features of pneumonia. Only two studies reported follow-
up testing, which determined a negative coronavirus using RT-PCR test and normal chest 
X-ray [24], and two negative coronavirus using respiratory swabs [30].  
3.4.9. Treatment of COVID-19 
Treatment of COVID-19 varied among the studies. Six patients with varying degrees 
of COVID-19 symptoms were hospitalized, and management of symptoms involved 
medication, such as azithromycin, remdesivir, oseltamivir, and enoxaparin. Other 
treatments alleviating COVID-19 symptoms included high flow oxygen [22], intubation 
[26,27], and non-invasive mechanical ventilation [31]. Three studies reported conservative 
at-home treatment of coronavirus symptoms as one patient had no features of pneumonia 
[21], one patient did not require admission to the hospital [28], and another patient was 
given antiviral medication [24]. Management of COVID-19 was not described in the 
remaining studies. 
3.4.10. Quality Analysis of Case Reports 
In total, three studies were of good quality, seven studies were of fair quality, and 
two studies were of poor quality (See Table S3). There was a lack of follow-up assessments 
for seven case reports and outcome measures that were undefined or undeterminable in 
three studies. Despite the lack of details, most case reports were able to provide unbiased 
reports of audio-vestibular symptoms. 
3.5. Cross-Sectional Studies Investigating Disease Impact  
3.5.1. Study Characteristics 
There were 17 clinical studies, including 8913 participants with an age range of 6 to 
98 years. Some studies reported an equal gender divide, and others reported variable 
ratios, such as Munro et al. [44] reporting 88% and Viola et al. [47] reporting 67% of the 
participants were males, as seen in Table 3. One study included other genders [33] (e.g., 
nonbinary and cisgender), and another study did not report the prevalence of symptoms 
in males and females [32]. The number of patients included ranged from 6 to 1420 in these 
studies, with most being conducted in Europe followed by Asia. There were seven studies 
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that took place in Europe from Italy [35,43,47], France [39,48], and England [44]. Lechien 
et al. [41] had participants from France, Italy, Spain, Belgium, and Switzerland. There were 
six studies from Asia reporting from India [45,46], Pakistan [36], Turkey [49–51], and 
China [42]. The three additional studies were located in Russia [32]; Egypt [37]; and 
internationally, including the USA, UK, Northern Ireland, France, Canada, Spain, 
Netherlands, Ireland, Sweden, and other countries [18,33].  
3.5.2. Study Designs and Outcomes 
Studies were both retrospective (e.g., Elibol [34], Lechien et al. [41], Liang et al. [42], 
Klopfenstein et al. [39], and Zayet et al. [48]) and prospective observational studies (e.g., 
Daikhes et al. [32], Karadaş and Sonkaya [38], Özçelik Korkmaz et al., [40], and Swain and 
Pani [46]). Data collection was completed via verbal questioning during ear, nose, and 
throat (ENT) examinations for all of the included studies. Outcome measures included 
self-reported questionnaires within six studies [33,36,37,40,43,47,]. Additionally, only one 
study used validated questionnaires (e.g., tinnitus handicap inventory (THI)) [35], and 
another study used a severity scale (i.e., visual analogue scale (VAS), ranging from 0 
(absent) to 10 (most severe) [47]. Sources of heterogeneity included different tinnitus 
reporting criteria, age groups, and study focus. Two studies included control groups, 
namely, Daikhes et al. [32], who had 30 controls included, and Freni et al. [35], who had 
20 controls with no history of hearing loss or tinnitus. Zayet et al. [48] included a control 
group who had Influenza and no COVID-19 symptoms.  
3.5.3. Pre-Existing Health Conditions 
Pre-existing health conditions were described in 11 studies that included 
hypertension, asthma, diabetes mellitus, cardiovascular disease, rheumatoid arthritis, 
arrhythmia, dyslipidemia, peptic ulcer, thyroid disease, musculoskeletal conditions, 
metabolic/endocrine conditions, neurological conditions, cancer, chronic obstructive 
pulmonary disease, gastroesophageal reflux disease, allergies, respiratory 
insufficiency/disease, chronic rhinosinusitis (CRS) with or without polyps, history of 
surgery for CRS, depression, allergic rhinitis, autoimmune diseases, chronic liver 
diseases/insufficiency, cerebrovascular disease, hyperlipidemia, anemia, renal 
failure/chronic kidney disease, sinonasal problems, hearing loss, tinnitus, vestibular 
disorders, immunosuppression, and other conditions not specified [34–37,39–43,48,44]. 
Some studies excluded participants with comorbidities such as patients with hearing loss 
or at risk of having a hearing loss (e.g., noise exposure, surgeries, ototoxic medication, or 
diseases that may lead to hearing loss) [32,46,47]. Other comorbidity exclusion criteria 
included psychiatric disorders, cardiovascular or circulatory disorders [47], treatment 
with new drugs, chronic nasal problems, recent head trauma, brain or nose operations, 
and severe respiratory failure [45]. Davis et al. [33] did not mention comorbidities; 
however, they excluded the following symptoms from the analysis: high blood pressure, 
low blood pressure, thrombosis, seizures, low oxygen levels, high blood sugar, and low 
blood sugar.  
3.5.4. Tinnitus Overview 
In total, 1763 participants reported tinnitus in the 17 included studies and an 
additional study by Beukes et al. [18]. This study did not directly investigate the COVID-
19 disease but identified seven individuals reporting tinnitus and four with hearing loss 
after contracting COVID-19 from the sample of 237 reporting COVID-19 symptoms, out 
of the 3103 participants. Prevalence ranged from 0.35% [41] to 67% [45] for the disease 
related studies. The variability was found even in larger studies as Lechien et al. [41] had 
a prevalence of 0.35% for 1420 participants and Davis et al. [33] a prevalence of 34% for 
3762 participants. Sensitivity analysis removing the outlier studies did not impact the 
results. The studies were not always clear if the tinnitus onset was post COVID or if it was 
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tinnitus that was exacerbated. As heterogeneity was high (I2 = 97.91, p <0.001), a random-
effect meta-analyses was conducted. The pooled prevalence estimate (Figure 2) for 
tinnitus associated with COVID-19 from these 17 cross-sectional studies and the Beukes 
et al. [18] study (18 studies) was 8% (CI: 5 to 13%). 
 
Figure 2. Forest plot for the estimated prevalence of tinnitus in suspected and probable COVID-19 cases. The 
individual study estimate, and the 95% CI are represented by center lines and their error bars, respectively. 
3.5.5. Tinnitus Characteristic 
As no standard standardized diagnostic criterion for tinnitus was used, great 
variability was found regarding tinnitus severity and characteristics, and not all studies 
described the tinnitus. Viola et al. [47] presented tinnitus descriptions for participants to 
select, indicating large variability in the tinnitus experienced. Amongst 43 patients, 17 
(39.5%) described tinnitus as recurrent (comes and goes away during the day), 10 (23.3%) 
as occasional (episodic, sporadic), 7 (16.3%) as continuous fluctuating with intensity 
changes throughout the day, 4 (9.3%) as persistent (always present, day and night), 3 
(7.0%) as pulsatile (synchronous with heartbeat), and 2 (4.6%) as continuous (always 
present with the same intensity, making it difficult to fall asleep). VAS mean score for 
tinnitus was 5, revealing an overall moderate severity across patients [47]. Freni et al. [35] 
reported a THI score of 6.6 ± 12.1 (THI scores of 0–16 are considered as no or slight 
handicap) and that for 10 patients tinnitus was initiated or worsened due to COVID-19. 
In a study focused on the pandemic impact [18], among those with pre-existing tinnitus 
who contracted COVID-19 (n = 237), 40% reported that their tinnitus became more 
bothersome, 54% reported no changes to their tinnitus, and 6% reported improvement in 
their tinnitus. Those reporting an improvement mentioned that they had gained new 
perspectives and realized that their tinnitus was not such a big problem compared with 
fighting to survive while hospitalized with COVID-19. For those reporting their tinnitus 
worsened, it is unclear whether reported changes were directly related to the virus or not. 
Other factors may have played a role, for instance, participants taking medications or 
vitamins to boost the immune response reported a significant increase in their tinnitus. 
Tinnitus location: One patient reported unilateral tinnitus (lateralized left) associated 
with aural pressure among eight identified self-reports of tinnitus [44], and the tinnitus 
location was not reported in other studies.  
Tinnitus onset: Tinnitus onset was reported from one day post-infection [40,42] and 
1-week post-infection by 11.5% (10.5%-12.5%) in the study by Davis et al. [33], increasing 
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to 26.2% (23.5%-29.1%) over 6–7 months post-COVID-19. Davis et al. [33] identified that 
tinnitus was one of the later symptoms to occur at approximately 7 weeks post-COVID-
19.  
Tinnitus duration: Few studies mentioned tinnitus duration, and where reported, 
great variation was found. In the study by Munro et al. [44], there were eight individuals 
with tinnitus, of whom three also reported a pre-existing hearing loss. Of these, one 
participant reported that the tinnitus resolved over time. Savtale et al. [45] revealed 120 
patients (66.66%) amongst 188 self-reported new-onset tinnitus lasting 5 days (median, 
interquartile range [IQR] 4–6). Liang et al. [42] revealed the average duration of tinnitus 
was 5 days. Özçelik Korkmaz et al. [40] revealed duration ranging from 1 to 9 days 
(median = 4). Davis et al. [33] reported that both tinnitus and hearing loss were likely to 
ramp up sharply in the first two months and continue to increase up to 6–7 months post 
COVID-19.  
Tinnitus management: Management of tinnitus was not described in any of the studies. 
This may be due to the unknown etiology between coronavirus and tinnitus and the 
inconsistency in defining and reporting tinnitus, leading to variability in estimates.  
3.5.6. Hearing Loss 
Of the 16 included cross-sectional studies, 10 also examined hearing loss as a possible 
symptom of COVID-19 (n = 495), although there was substantial variability in how studies 
assessed and reported hearing loss. Gender and age were, for instance, not reported in 
most studies except Swain and Pani [46] and Özçelik Korkmaz et al. [40]. Study designs 
included retrospective evaluation of medical records for 5 studies [32,34,39,46,48]; verbal 
questionnaire interviews [44,45]; and the use of self-reported symptoms questionnaires 
for 2 studies [33,40]. Only one study reported Hearing Handicap Inventory for Adults 
(HHIA) scores for all patients [35].  
The overall prevalence figures ranged from 0% [28] to 100% [45]. Swain and Pani [46] 
identified 28 patients ranging from 16 years to 52 years (mean = 28.2), with 15 (53.57%) 
females and 13 (46.42%) males with hearing loss after hospital discharge. When grouped 
by age, Özçelik Korkmaz et al. [40] found hearing loss prevalence was 50% (n = 3) for 
patients 60 years and older and 50% (n = 3) for those younger than 60 years, with two 
males and four females.  
Type of hearing loss: Where provided, hearing loss ranged from being mild to 
moderate in degree [45], high frequency in pattern [35,46], conductive [46], and 
sensorineural [45,46]. Although bilateral sensorineural hearing loss was identified, the 
majority included unilateral hearing loss (e.g., 83% of the sample by Munro et al. [44]).  
Onset and progression of hearing loss: Davis et al. [33] revealed that the incidence of 
hearing loss increased from 2.98% (CI: 2.47–3.54%) in week 1 to 6.42% (CI: 5.00–8.07%) of 
respondents in week 6–7. Another study reporting duration found hearing impairment 
lasting from 3 to 7 days (median = 4) [40], and Savtale et al. [45] identified self-reported 
new onset hearing loss lasting 13 days (median, 9.5–16.75 IQR). Freni et al. [35] revealed 
the appearance or worsening of hearing loss in 20 patients (40%), with an HHIA score of 
13.2 ± 14.9 during the active phase of symptomatology from COVID-19. After recovery 
(15 days after negative RT-PCR test), 9 patients reported the presence of hearing loss,  
with a lower total mean of the HHIA score of 4.24 ± 5.55 (p < 0.001). 
Assessment and management of hearing loss: Most studies relied on self-reports of 
hearing loss, and only one study undertook a full audiological evaluation consisting of 
tympanometry, acoustic reflex thresholds, and transient evoked otoacoustic emissions 
(TEOAEs) [32]. Pure tone audiometry was conducted in two studies [35,46], 
tympanometry in one study [46], and TEOAEs in three studies [32,35,46]. One study 
utilized a tuning fork test at a frequency of 512 Hz to examine audiologic function [45]. 
TEOAE amplitude was significantly worse in 22/28 COVID positive cases [46] and was 
also worse compared to individuals without COVID-19 [32,35]. Only one study among 
the others reported treatment for sudden sensorineural hearing loss (SSNHL) using 
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corticosteroid therapy, specifically oral prednisolone for three weeks along with vitamin 
B-complex and proton pump inhibitor daily [46]. 
3.5.7. Vestibular Deficits 
Reports of vestibular impairments were found in four clinical studies as a possible 
symptom of COVID-19. All studies assessed self-reported questionnaires regarding 
otologic symptoms of COVID-19. Among the studies, only one utilized a severity scale to 
investigate the severity of balance disorders [47]. Davis et al. [33] reported that 
dizziness/balance issues were most likely to persist after six months. In this study, 30–50% 
of the respondents experienced dizziness/balance issues after six months. Özçelik 
Korkmaz et al. [40] reported that two participants had a previous vestibular disorder, with 
31.8% of the participants having dizziness and 6% having true vertigo post-COVID-19. 
Dizziness was statistically significantly higher in women that were less than 60 years old, 
and true vertigo was only present in participants younger than 60 years old. The range of 
duration for true vertigo for participants was 1 to 5 days with a median of 3 days. For the 
duration of dizziness, the range was 2 to 13 days with a median of 6 days. Micarelli et al. 
[43] stated that 6.2% of the participants experienced vertigo/dizziness and 6.3% of the 
participants experienced disequilibrium. Vertigo or dizziness symptoms had duration 
ranges of 2 to 12 days, while disequilibrium was 2 to 14 days. In Viola et al. [47], 18.4% of 
the participants reported balance disorders after the diagnosis of COVID-19. Of those with 
balance deficits, 94.1% experienced dizziness and 5.9% experienced acute vertigo attacks. 
Fourteen (7.6%) had both tinnitus and an equilibrium disorder, while 7% experienced a 
migraine and an equilibrium disorder. There were 20 (58.8%) females and 14 (41.2%) 
males that experienced balance deficits. The severity of the equilibrium disorders was 
measured by the VAS. The mean score for the equilibrium disorders was 5 out of a 1–10 
rating. Management or treatment of vestibular impairments was not discussed in the 
studies.  
3.5.8. COVID-19 Testing 
All the studies used RT-PCR testing for the diagnosis of COVID-19 as part of the 
inclusion criteria, except for Viola et al. [47], who used an unspecified nasopharyngeal 
swab. Davis et al. [33] and Macarelli et al. [43] included those who had experienced 
COVID-19 symptoms but not been tested. Micarelli et al. [43] also required the 
participants to have no fever in the past 14 days or a negative test for COVID-19 to 
participate in the study. Iqbal et al. [36] and Kamal et al. [37] only included participants 
who had PCR testing, to evaluate the presence or absence of SARS-CoV-2.  
3.5.9. Treatment of COVID-19 
Treatment of COVID-19 was not always described, and some studies only stated that 
patients were hospitalized [33–35,40,44,47,45,46] or in intensive care units [36,37,39,48]. In 
Daikhes et al. [32], groups of drugs were used as treatments (antiviral, antimalarial, 
anticoagulants, and antibacterial). Lechien et al. [41] used oral treatment depending on 
symptoms such as analgesic drugs (paracetamol, nonsteroidal anti-inflammatory, oral 
corticosteroids, mucolytics, hydroxychloroquine), antibiotics (macrolides), and beta-
lactam antibiotics, along with antiviral drugs, pulmonary aerosols, and nasal treatments. 
Other treatments for COVID-19 symptoms included oxygen therapy [36,39,48], home 
remedies [36], and vitamins [37]. Liang et al. [42] stated that the treatment guidelines for 
COVID-19 issued by the National Health Committee of the People’s Republic of China 
were used for treatment. Micarelli et al. [43] did not provide information regarding the 
treatment of COVID-19. Furthermore, many of the clinical studies had patients who did 
not receive treatment. 
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3.5.10. Quality Analysis of Cross-Sectional Observational Studies 
Three studies were of good quality, seven studies were of fair quality, and no studies 
were of poor quality (Table S3).  
3.6. Pandemic Impact Studies: Comparing Tinnitus Before and during the Pandemic  
3.6.1. Study Characteristics 
There were three studies comparing tinnitus severity before and during the 
pandemic performed in Italy [50], Germany [51], and China [52], as summarized in Table 
4. The number of participants varied (16, 94, and 122, respectively). These studies focused 
on how the COVID-19 pandemic affected tinnitus rather than on how the actual COVID-
19 virus affected tinnitus. Therefore, COVID-19 testing (positive or negative) information 
was not included in the data collection for these studies. The THI questionnaire was used 
as part of the assessment of tinnitus severity for all three studies. As Anzivino et al.’s study 
[50] was a letter to the editor, the study was not detailed in terms of describing the age 
and gender characteristics of participants. In Schlee et al. [51] and Xia et al. [52], the mean 
age was similar, 54.0 (SD: 10.9) and 52.6 (SD: 14.7), respectively; however, regarding 
gender percentages, the male percentage in the participants was greater in Schlee et al. 
[51], at 65.5% and 48.3%, respectively. 
3.6.2. Tinnitus Characteristics 
Overall, the studies showed there was an increase in tinnitus severity during the 
pandemic. Anzivino et al. [50] found that the grade of tinnitus severity had increased by 
one level on the THI for a small sample tested (12 out of 16 participants) during the 
pandemic. Schlee et al. [51] found that although there was an increase in tinnitus severity 
on 122 patients during the pandemic compared with before, as measured by the THI and 
Mini-Tinnitus Questionnaire (Mini-TQ), this difference was not significant. Tinnitus 
severity was, however, significantly correlated to pandemic-related stress using the social 
isolation electronic survey to identify grief, frustration, stress, and nervousness. The study 
also revealed that the higher the participant’s neuroticism score, the more distinct was the 
worsening of the tinnitus. Xia et al. [52] identified significantly higher tinnitus severity 
during the pandemic (40 out of 100 for the THI for 99 patients) compared to before the 
pandemic (34 out of 100 for the THI for 89 patients) and that the effect of anxiety 
(measured by Self-rating Anxiety Scale; SAS) associated with the impact of the pandemic 
appeared to contribute to elevated tinnitus awareness.  
3.6.3. Tinnitus Treatments 
Xia et al. [52] reported that educational counselling resulted in improvements in the 
SAS, THI score, and tinnitus loudness test before the pandemic, but such treatments were 
less effective in 2020. The authors concluded that educational counselling was not enough 
for the stress and anxiety during the COVID-19 pandemic and provided evidence that 
anxiety is a contributing factor to tinnitus severity. 
3.6.4. Quality Analysis of Pandemic Impact Study Comparing Tinnitus before and 
during the Pandemic 
Anzivino et al.’s [50] study was rated as poor due to the lack of description of the 
participants (e.g., gender, age, and eligibility criteria), the lack of statistical analysis, lack 
of repeated outcomes measures, and the small sample size (n = 16). Schlee et al. [51] and 
Xia et al. [52] were rated as fair due to providing a relatively good description of the aim, 
eligibility criteria, outcome measures, and fair sample size. 
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3.7. Cross-Sectional Studies Investigating the Effects of the Pandemic on Pre-existing Tinnitus  
3.7.1. Study Characteristics 
There were two cross-sectional studies (Table 4) investigating the effect of the 
pandemic on pre-existing tinnitus at one point in time [18,49]. Although these studies tried 
to identify the incidence of tinnitus during the pandemic, most of the included 
participants had pre-existing tinnitus. Drawing conclusions regarding the impact of the 
pandemic on the incidence of tinnitus compared with the incidence before the pandemic 
can thus not be determined. 
3.7.2. Outcome Measures 
Beukes et al. [18] used the tinnitus handicap inventory screening (THI-S) versions to 
measure the severity of tinnitus, as well as an online survey that contained questions 
regarding demographics, contracting COVID-19, whether social distancing guidelines 
were followed, the emotional and financial toll of the pandemic, and the use of coping 
strategies. Naylor et al. [49] assessed the impact of the pandemic on those with hearing 
loss using an online survey that asked questions regarding behavior, emotions, hearing 
performance, practical problems (wearing hearing aids and masks), and tinnitus during 
the pandemic.  
3.7.3. Individual Study Descriptions 
To study a more heterogeneous tinnitus population, Beukes et al. [18] surveyed 3103 
individuals with tinnitus between May-June 2020. Although global representation was 
sought, the majority of the participants were from North America (49%) and Europe 
(47%), with a minority (4%) representing other world regions and a total number of 3103 
participants equally balanced in gender. Findings indicated that the pandemic had not 
altered tinnitus for the majority (67%), 31% reported their tinnitus was exacerbated during 
the pandemic, and 2% found their tinnitus was better. Tinnitus was found to be 
significantly more bothersome during the pandemic for females and younger adults 
under the age of 50. Additional mediating factors significantly exacerbating tinnitus 
included self-isolating, experiencing loneliness, sleeping poorly, and reduced levels of 
exercise. Increased depression, anxiety, irritability, and financial worries further 
significantly contributed to tinnitus being more bothersome during the pandemic period. 
Participants from the Naylor et al.’s [49] study consisted of 129 individuals with hearing 
loss that lived in Glasgow, Scotland. Ages ranged from 27 to 76 (mean = 64.4) years old 
with 48% female. Data were collected from May 29th to June 15th, 2020; therefore, the 
participants had experienced over 2 months of lockdown. Due to the focus on hearing 
loss, there was only one question about tinnitus in the online survey for Naylor et al. [49]; 
the primary outcome of the study was to determine the impact of the pandemic on those 
with hearing loss. Participants were grouped into those with worse hearing (n = 61) and 
better hearing (n = 68). Out of the 129 participants, 70 had pre-existing tinnitus. In the 
worst hearing group, 38 had tinnitus while the better hearing group had 32 participants 
with tinnitus. In response to the statement in the survey, “My tinnitus has been worse 
since lockdown started,” 42.1% agreed, 31.6% were neutral, and 26.3% disagreed in the 
worse hearing group. However, in the better hearing group, 18.8% agreed, 37.5% were 
neutral, and 43.8% disagreed. There was a non-significant trend toward tinnitus being 
worse during the pandemic for those with greater hearing loss. Participants explained that 
tinnitus was more noticeable when the world around them was quieter. Overall, the 
studies showed that there may be a trend for tinnitus to exacerbate during the pandemic; 
however, this did not pertain to the majority of participants with pre-existing tinnitus. 
Contributing factors may include gender, age, self-isolation, loneliness, lack of sleep and 
exercise, depression, anxiety, irritability, financial concerns, or a quieter environment.  
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3.7.4. Quality Analysis of Cross-Sectional Studies Investigating Effects of the Pandemic 
on Pre-Existing Tinnitus 
The quality analyses of these two cross-sectional studies were both rated as fair, as 
seen in Table 4. Guidelines for consistency of reporting in future COVID-19 studies are 
provided in Table 5 to help science progress and improve patient outcomes going 
forward.  
Table 5. Recommendations for future research investigating the impact of COVID-19 on audio-vestibular conditions. 
Study Design Considerations  Data Collection and Reporting Suggestions  
Including control groups with and without the presence of the 
disease or symptoms being investigated  
Reporting basic demographic information such as age, 
gender, and additional health and mental health 
difficulties.   
Utilizing standardized self-reported outcome measures to 
track the changes in severity of presenting symptoms  
Reporting how COVID-19 was tested and managed, 
and how severe the symptom presentation was  
Studying wider populations not only form one clinic or region 
Reporting possible pre-existing associated factors such 
as local or systemic infections; vascular or autoimmune 
disorders; and stress, anxiety, and depression.   
Undertaking audiometric assessments and comparing these 
with baseline audiograms or OAE results where available  
Describing the tinnitus presentation such as its onset, 
frequency, descriptions, location, duration, and if it 
changes or resolves   
Studies including longitudinal follow-up periods to identify 
the trajectory of the symptoms to indicate whether the tinnitus 
resolves or remain and if the severity changes   
Investigating psychosocial factors that may contribute 
such as stress, anxiety, and depression  
Providing management options to those presenting with 
audio-vestibular symptoms  
Reporting tinnitus or auditory treatments offered and 
their effects  
4. Discussion  
The purpose of this systematic review was to review the evidence regarding the effect 
of contracting COVID-19 on tinnitus and the effect of the wider pandemic on tinnitus. 
Until and including 31 March 2021, there were 33 published articles discussing these 
effects. These studies varied in study design and purpose. There were 28 investigating the 
impact of COVID-19 on tinnitus and five reporting the impact of the pandemic on tinnitus. 
Although not all countries published reports, there was a fair global representation, 
including two studies that attempted international data collection. This discussion 
highlights the main findings.  
4.1. The Effect of Contracting COVID-19 on Tinnitus  
No consistent profile regarding who may develop tinnitus post-COVID-19 was 
identified. A range of ages was affected (6 to 98 years) and there were variations in gender 
proportions, possibly attributed to different research designs. From this review, no 
consistent pattern was identified regarding the risk of developing tinnitus. Some 
individuals had pre-existing conditions such as head trauma, asthma, diabetes, 
hypertension, cancer, and hearing disorders, but others had no pre-existing comorbidities. 
COVID-19 factors that may have contributed were furthermore unclear as not all 
individuals were tested for the presence of COVID-19, and some studies relied on self-
reporting. When reported, the RT-PCR test was most frequently used. The severity of the 
COVID-19 symptoms also varied, resulting in some individuals being hospitalized, 
ventilated, and medicated, while others remained at home. It is not clear from any studies 
as to whether the severity of the infection or treatment provided for COVID-19 correlated 
with the tinnitus severity, presentation, or duration. From 17 included studies, the 
estimated prevalence was 8% (CI: 5 to 13%). This is between the prevalence rates reported 
by Almufarrij and Munro [10] of 14.8% (CI: 6.3 to 26.1) and Jafari et al. [11] of 4.5% (CI: 1.2 
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to 15.3). All three reviews included different studies due to different protocols followed 
but provide some insights into the possible expected prevalence from the published 
literature.  
The onset of the tinnitus post-COVID-19 was variable. This included reports of onset 
between 1 day [42] and 7 weeks post-onset. Interestingly, Davis et al. [33] reported that 
the incidence increased from 11.5% at 1-week post-infection to 26.2% by week 6–7 post-
COVID-19 and that tinnitus was one of the later symptoms to develop. Due to the 
prevalence of tinnitus being at least 11% [58] within the general adult population, it is 
difficult to determine if other factors may have contributed to the tinnitus experienced. 
Tinnitus duration also varied, with some reporting a resolution after 5 days (e. g., Liang 
et al. [42], Özçelik Korkmaz et al. [40], and Savtale et al. [45]) and Davis et al. [33] reporting 
tinnitus to increase in later months post COVID-19. Due to the sudden and rapid 
developments of COVID-19, there was not always the option for large-scaled studies due 
to the time pressures, and most studies were retrospective or observational cross-sectional 
studies. A lack of longitudinal tracking regarding the progression of tinnitus was not 
always incorporated, hence longer-term trajectories or the tinnitus presentations were not 
identified.  
Tinnitus presentations were often not provided. Viola et al. [47] found that tinnitus 
was more frequently recurrent and occasional as opposed to persistent and continuous, 
but only 43 individuals were included in this study. The tinnitus location varied between 
unilateral and bilateral presentations, although the location was often not described. It 
was not always clear whether there was pre-existing tinnitus. Beukes et al. [18] found that 
of those with pre-existing tinnitus who contracted COVID-19 (n = 237), 40% reported that 
their tinnitus became more bothersome, 54% reported no changes to their tinnitus, and 
6% reported improvement in their tinnitus, again indicating inconsistent consequences of 
COVID-19 on tinnitus.  
4.2. Characteristics of Other Auditory Vestibular Conditions  
Although not always reported, various individuals presented with both tinnitus 
and hearing loss, with unilateral SNHL being most commonly reported (e.g., Munro et 
al. [44]). Variability in the hearing loss severity was also found with ranges between mild 
to severe. Some studies reported that the hearing recovered [40,56], and others found that 
it deteriorated between 1 to 7 weeks post-COVID-19 [33]. Dizziness and vertigo were also 
reported, although the prevalence was lower. These auditory symptoms were reported to 
resolve by some and persist 6–7 months post COVID-19 by others (e.g., Davis et al. [33]). 
Studies identifying the mechanisms and associations of these symptoms with COVID-19 
as well as the trajectory of these symptoms are required.  
Although speculative, numerous pathogenesis have been proposed regarding the 
possible association between hearing loss and the SARS-CoV-2 virus. Findings by 
Daikhes et al. [32], Freni et al. [35], and Swain and Pani [46] regarding reduced TEOAE 
amplitudes have been supported by Mustafa [59], who found that high-frequency pure-
tone thresholds and TEOAE amplitudes were significantly worse in 20 asymptomatic 
COVID-19 PCR-positive cases when compared with 20 normal non-infected 
participants. This indicates that the SARS-CoV-2 virus could affect cochlear outer hair 
cell functioning. Further suggested mechanisms suggest that the SARS-CoV-2 infection 
together with serotonin release and blood coagulation may intertwine to activate 
platelets and drive SSNHL [60]. Excessive cytokine release and/or ischemic damage from 
thrombosis are furthermore suggested to increase oxidative damage, resulting in 
permanent hearing damage [61]. 
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4.3. The Impact of the Pandemic on Tinnitus Experiences  
A wide range of individuals reporting tinnitus during the pandemic was identified 
with variations in gender divides. Overall, these studies found that tinnitus severity often 
increased during the pandemic but not for all individuals. Stress, neuroticism, and anxiety 
were identified as contributing factors [51,52]. Beukes et al. [18] found that tinnitus was 
significantly more bothersome during the pandemic for females and younger adults 
under the age of 50. Additional mediating factors that significantly exacerbated tinnitus 
included self-isolating, experiencing loneliness, sleeping poorly, and reduced levels of 
exercise. Increased depression, anxiety, irritability, and financial worries further 
significantly contributed to tinnitus being more bothersome during the pandemic period. 
According to these studies, there is a correlation between the emotional toll of the 
pandemic and the severity of tinnitus in participants; however, there is a need for in-depth 
studies to determine certain factors contributing to the elevated tinnitus severity and what 
therapy or tools can be provided to counteract these factors. As these studies have 
generally included individuals who had pre-existing tinnitus, conclusions regarding the 
impact of the pandemic on the incidence of tinnitus compared with the incidence prior to 
the pandemic cannot be drawn.  
4.4. Limitations of the Evidence and Review Process  
Although this review aimed to conclude the presentation of tinnitus, these 
descriptions were generally not provided. This made concluding the risk factors, tinnitus 
characteristics, progression of the tinnitus, and other audio-vestibular deficits. Due to the 
variations in what was reported and how tinnitus and or audio-vestibular difficulties 
were measured, it made the synthesis incomplete. The results presented are limited due 
to variability in study design and approach as well as inconsistent use of outcome 
measures. Follow-up reporting was also poor. Clear descriptions of tinnitus were not 
provided in all the studies, making synthesis of the studies difficult. Only a few of the 
studies for instance specifically described the tinnitus or investigated the onset, duration, 
severity, characteristics, and psychological impact thereof. Although overall the study 
quality was fair and represented unbiased reports, quality was compromised as all but 
three studies had no control or comparator group. Furthermore, self-reported assessment 
measures were generally included, relying on participant’s recall of symptoms and 
progression. Further factors of bias included questionnaire distribution through tinnitus 
associations, which could furthermore inflate pooled estimates of tinnitus or only 
participants from one region.  
4.5. Implications for Practice, Policy, and Future Research  
These findings have important implications for clinical services. As identified by 
Almufarrij and Munro [10], tinnitus is the most prevalent audio-vestibular symptom 
(14.8%) post COVID-19. Health professionals who may be involved with COVID-19 
patients should be mindful that contacting COVID-19 may lead to tinnitus and other 
audiovestibular difficulties and such individuals should be directed to appropriate care. 
The COVID-19 pandemic undoubtedly disrupted and transformed usual healthcare 
services. Raising greater awareness among healthcare providers is required, due to the 
impact the COVID-19 virus and wider pandemic factors have on tinnitus and other 
audiological conditions. Despite studies identifying bothersome tinnitus, most did not 
discuss how tinnitus was managed. Xia et al. [52] mentioned that educational counselling 
that was normally helpful was not as effective for those with bothersome tinnitus during 
the pandemic. They put this down to needing management strategies that addressed 
anxiety and the increased stress during the pandemic. Those presenting with bothersome 
tinnitus during the pandemic or post COVID-19 may thus require different tinnitus 
management approaches.  
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Those with tinnitus often mention that they are unsupported as healthcare 
professionals are not understanding of the difficulties they face due to tinnitus and 
hearing loss [62,63]. Educating healthcare professionals specifically question experiences 
of any such symptoms, so that these individuals can be directed to the most appropriate 
care. Patient associations and audiologists should also be available to reassure and help 
those now experiencing tinnitus or with more bothersome tinnitus. Specific needs of those 
with tinnitus identified during the COVID-19 pandemic can be used by healthcare 
providers to shape future tinnitus services. These include a wider range of support for 
tinnitus and hearing-related difficulties, including more affordable hearing healthcare 
such as hearing aids and hearing protection. Those with tinnitus furthermore desire 
means of social support and education to the general population regarding the impact of 
tinnitus [62,63]. They also indicated the need for support to better deal with the increased 
stress and anxiety related to the pandemic. Individuals with tinnitus indicated that 
tinnitus-related research should be prioritized, including searching for tinnitus cures. 
Overall, there is a need for (a) understanding professional support and access to 
multidisciplinary experts, (b) a greater range of therapies and resources, (c) access to more 
information about tinnitus, (d) prioritizing tinnitus research, and (e) more support for 
hearing protection and hearing loss prevention. Patient organizations and professionals 
should be encouraged to work together to provide improved outlets for tinnitus care. 
Most importantly, digital therapeutical approaches should be prioritized to provide 
psychological interventions to those suffering from tinnitus and not able to access services 
due to demand on healthcare as well as not having access to services such as these, which 
are seen as low priority by hearing healthcare professionals during the pandemic [64]. 
Several studies across the globe have demonstrated the efficacy and effectiveness of 
Internet-based cognitive behavioral therapy (ICBT) for tinnitus [65–68], although not 
many programs are available for individuals. For this reason, clinicians and policymakers 
need to consider alternative ways of offering tinnitus services using teleaudiology 
approaches.  
The wider pandemic effect, such as the impact of the use of non-transparent face 
masks hampering lip-reading and face coverings reducing the acoustic transmission, 
attenuating the sound, and preventing lip reading, makes it difficult for those with 
auditory difficulties, especially those with greater difficulties, e.g., cochlear implant users. 
A study of 59 patients with hearing loss attending hospital appointments in Italy indicated 
that 37% reported moderate and 24% severe hearing difficulties [69]. These difficulties 
may contribute to the reports of increased anxiety during the pandemic for individuals 
with hearing loss, as demonstrated by a study focusing on 56 Iranian hard of hearing and 
deaf adolescence [70]. Support for those with hearing loss and other auditory symptoms 
is thus required.  
While the current literature provides some early understanding of the link between 
COVID-19 and tinnitus, due to limitations in terms of study design as well as issues with 
reporting of study findings, the conclusions drawn from this review are preliminary.  
5. Conclusions 
This review has been helpful in identifying the impact of both COVID-19 and the 
pandemic on tinnitus. Findings were limited to the quality of the research presented. This 
review identified a need for consistency in reporting and gathering data to be able to 
synthesis information. This review provides a foundation on which further robust 
research can be designed. What is important is investigating the mechanisms of these 
changes. It is not known if tinnitus and hearing loss can be directly attributed to the 
COVID-19 virus or whether they are attributed to other factors. These may include the 
impact of receiving critical care, including ototoxic medications [71], especially for those 
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with a possible greater vulnerability to ototoxicity [72]. The precise pathophysiological 
mechanisms causing tinnitus and other auditory-related symptoms remain unclear, and 
more research is required to further investigate these mechanisms.  
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